Stay updated on Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.

Latest updates to the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page’s revision/build identifier was updated from v3.5.2 to v3.5.3, reflecting a minor website release without changing the displayed study record.SummaryDifference0.1%

- Check28 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check71 days agoChange DetectedPage revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check93 days agoChange DetectedA minor revision tag was updated from v3.4.1 to v3.4.2, with no substantive changes to study content or page elements. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check101 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1. This is a minor metadata update that does not affect study details or user interactions; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.